Patanjali Secures IRDAI Approval for ₹4,500 Crore Insurance Acquisition

The Insurance Regulatory and Development Authority of India (IRDAI) has officially given the green light to a consortium led by Patanjali Ayurved for its ambitious acquisition of Magma General Insurance. This significant approval paves the way for the completion of a deal valued at approximately ₹4,500 crores. The consortium, which includes Patanjali Ayurved Ltd along with several foundations such as S.R. Foundation, RITI Foundation, RR Foundation, Suruchi Foundation, and Swati Foundation, is set to acquire shares from the current shareholders of the insurance company. With this regulatory endorsement, the consortium is now positioned to move forward with the share acquisition, adhering to the stipulations established by the IRDAI. The approval is valid for a period of three months, starting from July 28, 2026, during which the entire transaction must be finalized.

The IRDAI's approval was granted under Section 6A of the Insurance Act of 1938, in conjunction with the IRDAI (Registration, Capital Structure, Transfer of Shares and Amalgamation of Insurers) Regulations of 2024. It is important to note that the transfer of ownership will only be executed once all necessary contractual, regulatory, and closing procedures have been fulfilled. This approval signifies a pivotal moment for Patanjali Ayurved as it marks the company's entry into the competitive insurance sector in India. The move represents a strategic expansion for the Baba Ramdev-led conglomerate, which has primarily focused on fast-moving consumer goods (FMCG), healthcare, and wellness products. By venturing into insurance, Patanjali is poised to broaden its market reach and diversify its business portfolio significantly.